Question Everything. See who's reporting it.

Biosimilars cut cancer immunotherapy costs in India

Source: Times of India

The story in brief

Biosimilar drugs are making immunotherapy more affordable for cancer patients in India, with nivolumab's biosimilar showing effectiveness in 25 tumours. Doctors report a 50% rise in prescriptions as patients now afford the treatment at Rs 30,000 per cycle. A TMC study found only 2.8% of eligible patients received immunotherapy in 2022, but prescriptions have surged. Survival rates for melanoma patients have jumped from 5% to 50% with immunotherapy.

NEWXFree on Android and iPhone. Open in NEWX